By Ben Glickman

Amgen has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

Wezlana was approved as a biosimilar to and interchangeable with Stelara for treating adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease and moderate to severely active ulcerative colitis.

The treatment is also approved for treating patients 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis.

A biosimilar is a treatment that has no clinically meaningful difference from another treatment already approved by the FDA.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

October 31, 2023 19:20 ET (23:20 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Amgen.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Amgen.